Bioequivalence Study of Sorafenib Tablet and Nexavar
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, 3-way reference replicated crossover bioequivalence study of
sorafenib 200 mg tablet and nexavar (reference) following a 200 mg dose in healthy subjects
under fasting conditions.